Inactive Instrument

Weifa ASA

WEIFA

NO0010308240

Aqualis ASA Announces New Appointment

February 27, 2014 at 11:06 am EST

Aqualis ASA at its Extraordinary General Meeting, which was held February 27, 2014, has elected Glen Rodland as new chairman of the Board. Reuben Segal is elected as new Director and Martin Nes is elected as Deputy Director.

Latest news about Weifa ASA

Weifa ASA Announces Board Appointments	17-10-17	CI
Karo Pharma AB (OM:KARO) completed the acquisition of Weifa ASA (OB:WEIFA) from Holta Life Sciences AS, Watrium AS and others.	17-10-05	CI
An unknown buyer acquired 9.1% stake in Weifa ASA (OB:WEIFA) from MVN Event Driven Master Fund Limited fund managed by MVN Asset Management Limited and MVN Asset Management Limited.	17-09-25	CI
Weifa ASA(OB:WEIFA) dropped from S&P Global BMI Index	17-09-18	CI
Karo Pharma AB (OM:KARO) entered into a transaction agreement to make an offer to acquire Weifa ASA (OB:WEIFA) from Holta Life Sciences AS, Watrium AS and others for NOK 1.3 billion.	17-08-23	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Provides Earnings Guidance for the Year 2017	17-07-13	CI
Weifa ASA Announces Dividend, Payable on June 8, 2017	17-05-30	CI
Weifa ASA Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2016	17-04-28	CI
The mutual funds managed by Nordea Funds Oy acquired an additional 0.54% stake in Weifa ASA (OB: WEIFA).	17-03-19	CI
Weifa ASA Proposes Dividend for the Fourth Quarter of 2016, Payable on June 8, 2017	17-02-16	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	17-02-16	CI
Weifa Announces New License Agreement with AFT Pharmaceuticals for Nordic Rights to Groundbreaking Product Line Within Pain Management	17-01-12	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016; Provides Earnings Guidance for 2016	16-10-25	CI
Weifa ASA to Launch Lbux(R) 200 mg Soft Capsules to Strengthen its Pain Relief Portfolio	16-10-11	CI
Weifa ASA Launches Solvivo(R) Lozenges	16-09-14	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for Full Year of 2016	16-08-25	CI
Weifa ASA Announces the Launch of Zonat Tablets	16-08-10	CI
Weifa ASA (OB:WEIFA) announces an Equity Buyback for 20,000 shares, for NOK 0.02 million.	16-07-06	CI
Tranche Update on Weifa ASA (OB:WEIFA)'s Equity Buyback Plan announced on July 6, 2016.	16-07-06	CI
Weifa ASA authorizes a Buyback Plan.	16-07-05	CI
Weifa ASA's Equity Buyback announced on July 6,2016 has closed with 20,000 shares for NOK 0.02 million.	16-07-05	CI
Weifa ASA Signs Distribution Agreement with Fysioline Group	16-06-06	CI
Weifa ASA Declares Dividend, Payable on June 10, 2016	16-06-01	CI
Weifa ASA Proposes Dividend for First Quarter of 2016; Reports Earnings Results for the First Quarter of 2016; Announces Future Product Launches; Provides Earnings Guidance for the Year 2016	16-04-26	CI
Weifa ASA Secures New Loan Agreement with DNB	16-03-21	CI

Chart Weifa ASA

Duration

Period

More charts

Company Profile

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B

Generic Pharmaceuticals